Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones maintains an Outperform rating on Corvus Pharma (NASDAQ:CRVS) and raises the price target from $7 to $8.
May 07, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer maintains an Outperform rating on Corvus Pharma and raises the price target from $7 to $8.
The upgrade in the price target by a reputable analyst like Jeff Jones from Oppenheimer suggests a strong confidence in Corvus Pharma's future performance. This is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100